Maxalt

Maxalt is a triptan drug used for the treatment of migraine headaches. It is a selective 5-hydroxytryptamine1 receptor subtype agonist.

Medicinal name:
  • Rizatriptan 10 MG Oral Tablet [Maxalt]
  • Rizatriptan 10 MG Disintegrating Oral Tablet [Maxalt]
  • Rizatriptan 5 MG Disintegrating Oral Tablet [Maxalt]
  • Rizatriptan 5 MG Oral Tablet [Maxalt]

Maxalt - Pharmacology:

Maxalt binds with high affinity to human 5-HT1B and 5-HT1D receptors leading to cranial blood vessel constriction.

Maxalt mini report

Maxalt NDA
NDA - A product marketed under an approved New Drug Application
Maxalt HUMAN PRESCRIPTION DRUG
HUMAN PRESCRIPTION DRUG
Maxalt global name
rizatriptan benzoate
Start - Stop data
START DATA:
1998-Jun-29
Start - Stop data
STOP DATA
not occurred

Maxalt for patients

Migraine or treatment with MAXALT may cause somnolence in some patients. Dizziness has also been reported in some patients receiving MAXALT. Patients should, therefore, evaluate their ability to perform complex tasks during migraine attacks and after administration of MAXALT. Physicians should instruct their patients to read the patient package insert before taking MAXALT.

Maxalt Interactions

Propranolol: Maxalt 5 mg should be used in patients taking propranolol, as propranolol has been shown to increase the plasma concentrations of rizatriptan by 70%.

Ergot-containing drugs: Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and rizatriptan within 24 hours is contraindicated.

Other 5-HT1 agonists: The administration of rizatriptan with other 5-HT1 agonists has not been evaluated in migraine patients. Because their vasospastic effects may be additive, coadministration of rizatriptan and other 5-HT1 agonists within 24 hours of each other is not recommended.

Selective serotonin reuptake inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists. If concomitant treatment with rizatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised. No clinical or pharmacokinetic interactions were observed when Maxalt 10 mg was administered with paroxetine.

Monoamine oxidase inhibitors: Maxalt should not be administered to patients taking MAO-A inhibitors and non-selective MAO inhibitors; it has been shown that moclobemide (a specific MAO-A inhibitor) increased the systemic exposure of rizatriptan and its metabolite.

Drug/Laboratory Test Interactions: Maxalt is not known to interfere with commonly employed clinical laboratory tests.

Maxalt Contraindications

MAXALT should not be given to patients with ischemic heart disease (e.g., angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm, including Prinzmetals variant angina, or other significant underlying cardiovascular disease.

Because MAXALT may increase blood pressure, it should not be given to patients with uncontrolled hypertension .

MAXALT should not be used within 24 hours of treatment with another 5-HT1 agonist, or an ergotamine-containing or ergot-type medication like dihydroergotamine or methysergide. MAXALT should not be administered to patients with hemiplegic or basilar migraine.

Concurrent administration of MAO inhibitors or use of rizatriptan within 2 weeks of discontinuation of MAO inhibitor therapy is contraindicated. MAXALT is contraindicated in patients who are hypersensitive to rizatriptan or any of its inactive ingredients.

Manufacturers name:

  • Rebel Distributors Corp
  • Physicians Total Care, Inc
  • STAT RX USA LLC
  • Merck Sharp & Dohme Corp
  • Lake Erie Medical DBA Quality Care Products LLC

Generic name, Overdose, Half Life Maxalt, Food Interactions, Chemical, etc..

Maxalt see also FDA report Anise

Pain Relief

Chemical structure:
N N N N N H H H H H H H H H H H H H H H H H H H C15H19N5 2D chemical structure C15H19N5 SVG | 2D structure Rizatriptan chemical names, chemical properties, classification C15H19N5